+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia

Zeitschrift für Kardiologie 75(12): 757-763
Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia
The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 .times. AV nodal reentrant tachycardia, 9 .times. Wolff-Parkinson-White syndrome, 4 .times. paroxysmal atrial fibrillation, 10 .times. recurrent ventricular tachycardia). Electrophysiologic studies were performed before and after intravenous infusion of 1.5 mg/kg body weight diprafenone in a period of 10 minutes. Diprafenone prolonged the mean RR interval during sinus rhythm from 690 .+-. 109 ms to 789 .+-. 93 ms and the maximal sinus node recovery time from 1081 .+-. 216 ms to 1300 .+-. 398 ms (p < 0.001). The effective refractory period of the right atrium increased from 195 .+-. 22 ms to 210 .+-. 28 ms (p < 0.01) and of the right ventricle from 220 .+-. 20 ms to 235 .+-. 20 ms (p < 0.001). Diprafenone produced a prolongation of the antegrade effective refractory period of the AV node from 260 .+-. 35 ms to 294 .+-. 39 ms (p < 0.01) and of the retrograde effective refractory period from 265 .+-. 76 ms to 400 .+-. 130 ms (p < 0.001). The effective refractory periods of the Kent bundle increased: antegrade from 299 .+-. 45 ms to 413 .+-. 133 ms, retrograde from 252 .+-. 33 ms to 286 .+-. 169 ms (p < 0.05). Suppression of inducibility was observed in 12 of 17 patients with supraventricular reentrant tachycardia, in 5 of 8 patients with atrial fibrillation and in 7 of 10 patients with recurrent ventricular tachycardia. The rate of supraventricular tachycardias decreased under the influence of the substance. - Thus, diprafenone is effective in the therapy of patients with recurrent supraventricular and ventricular tachycardia.

Accession: 005349295

PMID: 3825226

Related references

Diprafenone electrophysiologic effects in patients with supraventricular and ventricular tachycardia. American Heart Association Monograph (124): II-99, 1986

Electrophysiologic effects of diprafenone a new class ic antiarrhythmic agent with additional beta sympatholytic activity in patients with sustained ventricular tachycardia. European Heart Journal 13(ABSTR SUPPL): 214, 1992

Clinical and electrophysiologic variants of false ventricular tachycardia (supraventricular tachycardia with wide QRS complex). Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova 85(7): 959-976, 2000

The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricular tachycardia with anterograde conduction over an accessory pathway. Pacing and Clinical Electrophysiology 17(9): 1515-1524, 1994

The electrophysiologic effects of recainam in supraventricular tachycardia. European Heart Journal 9(ABSTR SUPPL 1): 51, 1988

Electrophysiologic characteristics of ventricular extrastimulation-induced dissipation of functional bundle branch block associated with supraventricular tachycardia. Journal of Cardiovascular Electrophysiology 12(8): 928-934, August, 2001

Initiation and termination of ventricular tachycardia by supraventricular stimuli. Incidence and electrophysiologic determinants as observed during programmed stimulation of the heart. American Journal of Cardiology 46(4): 576-582, 1980

Electrophysiologic effects of penticainide in patients with supraventricular tachycardia. Zeitschrift für Kardiologie 79(10): 725-731, 1990

Electrophysiologic effects of diltiazem hydrochloride on supraventricular tachycardia. American Journal of Cardiology 49(3): 621-628, 1982

Cibenzoline electrophysiologic effects in patients with supraventricular tachycardia. European Heart Journal 10(ABSTR SUPPL): 302, 1989